"Depending on quality,
efficacy and cost, if payers determine that it is optimal to prefer generic
Truvada over brand Descovy, then yes, I believe Descovy will lose market share
across the board. This would include when used for PrEP."
— Mesfin Tegenu, president of PerformRx, spoke with AIS's RADAR on Drug Benefits about
UnitedHealthcare's decision to drop Gilead's Descovy from its commercial
formularies, and why other payers are likely to follow.
No comments:
Post a Comment